Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial

Fig. 4

Microalbumin over Creatinine ratio. Microalbumin: Creatinine ratio shown as line graphs over three visits. Between visit 1 and 2, the Lina and placebo line trajectories are similar, however between visit 2 and 3, there is a sharp drop in the line trajectory particularly for Lina group. This may indicate improvement in renal function with Linagliptin, gradually over a 12-week period. This observation (p value) was not statistically significant

Back to article page